Solaris Pharma Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SOLARIS PHARMA CORP, and what generic and branded alternatives to SOLARIS PHARMA CORP drugs are available?
SOLARIS PHARMA CORP has five approved drugs.
Drugs and US Patents for Solaris Pharma Corp
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solaris Pharma Corp | TAZAROTENE | tazarotene | GEL;TOPICAL | 213644-001 | Mar 20, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Solaris Pharma Corp | TAZAROTENE | tazarotene | GEL;TOPICAL | 213644-002 | Mar 20, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Solaris Pharma Corp | ESTRADIOL | estradiol | GEL, METERED;TRANSDERMAL | 216160-001 | Apr 22, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Solaris Pharma Corp | CLINDAMYCIN PHOSPHATE AND TRETINOIN | clindamycin phosphate; tretinoin | GEL;TOPICAL | 212845-001 | Feb 10, 2022 | AB2 | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.